Severe Aplastic Anemia

Hematology·MeSH: Anemia, Aplastic

13 drugs in development·7 companies·6 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
promacta	Novartis AG (NVS)

Phase 3(6)

Drug	Company
cyclosporine	Filana Therapeutics Inc. (FLNA)
cyclosporine	Structure Therapeutics Inc. (GPCR)
cyclosporine	Crinetics Pharmaceuticals, Inc. (CRNX)
Fludarabine	Crinetics Pharmaceuticals, Inc. (CRNX)
horse anti-thymocyte globulin	Crinetics Pharmaceuticals, Inc. (CRNX)
rabbit anti-thymocyte globulin	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(2)

Drug	Company
Haploidentical donor bone marrow transplant	Sanofi (SNY)
Unrelated donor bone marrow transplant	Sanofi (SNY)

Phase 1(3)

Drug	Company
2D UC-MSC group	Accustem Sciences Inc. (ACUT)
3D hypoxia-preconditioned UC-MSC group	Accustem Sciences Inc. (ACUT)
hemaxellerate	Regen BioPharma Inc (RGBPP)

Preclinical(1)

Drug	Company
hemaxellarate	Regen BioPharma Inc (RGBPP)

BioSniper tracks 13 drugs in development for Severe Aplastic Anemia across 7 companies.

There are 6 clinical trials targeting Severe Aplastic Anemia tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.